Skip to main content

Table 1 Patient characteristics

From: A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

Demographic or Clinical Characteristic

Number of Patients (n = 61)

Percentage (%)

Gender

 Male

34

56

 Female

27

44

Age, years

  ≤ 59

44

72

  > 59

17

28

ECOG PS

 0

17

28

 1

44

72

Primary tumor site

 Stomach

47

77

 Gastroesophageal junction

14

23

Prior surgery of primary tumor

 Yes

40

66

 No

21

34

Sites of metastatic disease

 Abdominal lymph node

34

56

 Liver

27

44

 Primary

14

23

 Lung

11

18

 Ovarian

10

16

 Distant lymph node

10

16

 Peritoneum

9

15

 Others

11

18

First-line chemotherapy

 5-FU/capecitabine + oxaliplatin

13

21

 ECF/EOF/EOX

34

56

 5-FU plus TXT/PTX

13

21

 Capecitabine

1

2

  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, PS performance status, 5-FU 5- fluorouracil, ECF epirubicin, cisplatin, 5-FU, EOF epirubicin, oxaliplatin, 5-FU, EOX epirubicin, capecitabine, oxaliplatin, TXT, docetaxel, PTX, paclitaxel